Universiteit Leiden

nl en

NWO awards funding for LACDR research project to develop novel engineering approaches to study cancer immunity

As part of the HTSM2017 funding program, the LACDR division for Systems Biomedicine and Pharmacology received 1.08 million euros for a research project to develop novel engineering approaches to fight cancer.

These approaches will enable diagnosis and characterization of cancer immunity at an unprecedented resolution and will be employed to develop individualized treatment strategies.

The project will be led by LACDR researchers Alireza Mashaghi and Thomas Hankemeier, in collaboration with Ron Heeren from Maastricht University. The work will be done in close collaboration with several industrial partners including Agios Pharmaceuticals (Boston), which are heavily involved in anti-cancer therapeutics and, in particular, cancer immunotherapy.